protagonist therapeutics inc - PTGX
PTGX
Close Chg Chg %
81.36 3.87 4.76%
Pre-Market
85.23
+3.87 (4.76%)
Volume: 1.05M
Last Updated:
Jan 14, 2026, 4:00 PM EDT
Company Overview: protagonist therapeutics inc - PTGX
PTGX Key Data
| Open $80.85 | Day Range 80.47 - 85.29 |
| 52 Week Range 33.70 - 96.54 | Market Cap $5.02B |
| Shares Outstanding 62.52M | Public Float 58.92M |
| Beta 2.26 | Rev. Per Employee N/A |
| P/E Ratio 126.70 | EPS $0.76 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 831.31K |
PTGX Performance
| 1 Week | 6.25% | ||
| 1 Month | -0.95% | ||
| 3 Months | 9.97% | ||
| 1 Year | 131.48% | ||
| 5 Years | 249.73% |
PTGX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
13
Full Ratings ➔
About protagonist therapeutics inc - PTGX
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
PTGX At a Glance
Protagonist Therapeutics, Inc.
7707 Gateway Boulevard
Newark, California 94560-1160
| Phone | 1-510-474-0170 | Revenue | 434.43M | |
| Industry | Pharmaceuticals: Major | Net Income | 275.19M | |
| Sector | Health Technology | 2024 Sales Growth | 624.055% | |
| Fiscal Year-end | 12 / 2025 | Employees | 126 | |
| View SEC Filings |
PTGX Valuation
| P/E Current | 126.697 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 9.128 |
| Price to Sales Ratio | 5.782 |
| Price to Book Ratio | 3.489 |
| Price to Cash Flow Ratio | 13.64 |
| Enterprise Value to EBITDA | 8.225 |
| Enterprise Value to Sales | 4.843 |
| Total Debt to Enterprise Value | 0.005 |
PTGX Efficiency
| Revenue/Employee | 3,447,880.952 |
| Income Per Employee | 2,184,031.746 |
| Receivables Turnover | 2.578 |
| Total Asset Turnover | 0.786 |
PTGX Liquidity
| Current Ratio | 12.482 |
| Quick Ratio | 12.482 |
| Cash Ratio | 8.838 |
PTGX Profitability
| Gross Margin | 99.318 |
| Operating Margin | 58.201 |
| Pretax Margin | 64.316 |
| Net Margin | 63.344 |
| Return on Assets | 49.808 |
| Return on Equity | 54.386 |
| Return on Total Capital | 40.105 |
| Return on Invested Capital | 53.836 |
PTGX Capital Structure
| Total Debt to Total Equity | 1.609 |
| Total Debt to Total Capital | 1.584 |
| Total Debt to Total Assets | 1.455 |
| Long-Term Debt to Equity | 1.534 |
| Long-Term Debt to Total Capital | 1.509 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Protagonist Therapeutics Inc - PTGX
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 27.36M | 26.58M | 60.00M | 434.43M | |
Sales Growth
| -4.44% | -2.84% | +125.73% | +624.06% | |
Cost of Goods Sold (COGS) incl D&A
| 2.77M | 1.03M | 3.31M | 2.96M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 2.77M | 1.03M | 3.31M | 2.96M | |
Depreciation
| 2.77M | 1.03M | 3.31M | 2.96M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | -62.81% | +220.93% | -10.54% | |
Gross Income
| 24.58M | 25.55M | 56.69M | 431.47M | |
Gross Income Growth
| - | +3.93% | +121.88% | +661.13% | |
Gross Profit Margin
| +89.86% | +96.12% | +94.48% | +99.32% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 153.53M | 156.92M | 150.34M | 178.63M | |
Research & Development
| 129.11M | 126.22M | 120.16M | 138.13M | |
Other SG&A
| 24.42M | 30.71M | 30.18M | 40.50M | |
SGA Growth
| +63.58% | +2.21% | -4.19% | +18.82% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (128.94M) | (131.37M) | (93.65M) | 252.84M | |
Non Operating Income/Expense
| 294.00K | 3.98M | 14.70M | 26.57M | |
Non-Operating Interest Income
| 443.00K | 4.06M | 14.90M | 26.32M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | -100.00% | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (128.65M) | (127.39M) | (78.95M) | 279.41M | |
Pretax Income Growth
| -95.38% | +0.98% | +38.02% | +453.88% | |
Pretax Margin
| -470.27% | -479.26% | -131.59% | +64.32% | |
Income Tax
| - | - | (3.10M) | 4.22M | - |
Income Tax - Current - Domestic
| - | - | - | 4.22M | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | 3.10M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (125.55M) | (127.39M) | (78.95M) | 275.19M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (125.55M) | (127.39M) | (78.95M) | 275.19M | |
Net Income Growth
| -89.80% | -1.47% | +38.02% | +448.54% | |
Net Margin Growth
| -458.94% | -479.26% | -131.59% | +63.34% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (125.55M) | (127.39M) | (78.95M) | 275.19M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (125.55M) | (127.39M) | (78.95M) | 275.19M | |
EPS (Basic)
| -2.7103 | -2.5976 | -1.3909 | 4.4697 | |
EPS (Basic) Growth
| -40.93% | +4.16% | +46.45% | +421.35% | |
Basic Shares Outstanding
| 46.32M | 49.04M | 56.76M | 61.57M | |
EPS (Diluted)
| -2.7103 | -2.5976 | -1.3909 | 4.2286 | |
EPS (Diluted) Growth
| -40.93% | +4.16% | +46.45% | +404.02% | |
Diluted Shares Outstanding
| 46.32M | 49.04M | 56.76M | 65.08M | |
EBITDA
| (126.17M) | (130.34M) | (90.34M) | 255.81M | |
EBITDA Growth
| -93.43% | -3.31% | +30.69% | +383.16% | |
EBITDA Margin
| -461.20% | -490.35% | -150.57% | +58.88% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 95.923 | |
| Number of Ratings | 13 | Current Quarters Estimate | -0.579 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 0.838 | |
| Last Quarter’s Earnings | -0.64 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.657 | Next Fiscal Year Estimate | -0.995 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 10 | 10 | 13 | 10 |
| Mean Estimate | -0.58 | 0.14 | 0.84 | -1.00 |
| High Estimates | 0.06 | 5.53 | 5.04 | 0.99 |
| Low Estimate | -1.24 | -1.01 | -2.36 | -2.13 |
| Coefficient of Variance | -68.25 | 1,419.71 | 331.56 | -105.10 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 11 | 11 | 12 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Protagonist Therapeutics Inc - PTGX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Protagonist Therapeutics Inc - PTGX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 8, 2026 | Arturo Molina Chief Medical Officer | 32,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Asif Ali Chief Financial Officer | 32,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Asif Ali Chief Financial Officer | 86,665 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Bryan Giraudo Director | 3,762 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Bryan Giraudo Director | 17,825 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | William D. Waddill Director | 3,762 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | William D. Waddill Director | 7,825 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Sarah A. O'Dowd Director | 3,762 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Sarah A. O'Dowd Director | 7,825 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Dinesh V. Patel President and CEO; Director | 120,200 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Dinesh V. Patel President and CEO; Director | 614,943 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Harold E. Selick Director | 3,762 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Harold E. Selick Director | 46,546 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Lewis T. Williams Director | 3,762 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Lewis T. Williams Director | 7,825 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Arturo Molina Chief Medical Officer | 106,780 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 17, 2025 | Arturo Molina Chief Medical Officer | 47,785 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 17, 2025 | Arturo Molina Chief Medical Officer | 69,063 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 17, 2025 | Arturo Molina Chief Medical Officer | 83,892 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $55.74 per share | 4,676,140.08 |
| Mar 17, 2025 | Asif Ali Chief Financial Officer | 62,821 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $58.73 per share | 3,689,477.33 |